C. Dávila-Fajardo

发表

Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty.

P. Carmona-Sáez, X. Díaz-Villamarín, C. Dávila-Fajardo, 2016, Pharmacogenomics.

Results of genotype-guided antiplatelet therapy in patients who undergone percutaneous coronary intervention with stent.

C. Dávila-Fajardo, L. J. Martínez-González, J. Sánchez-Ramos, 2016, International journal of cardiology.

Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention

G. Patrinos, T. Katsila, S. Wordsworth, 2019, The Pharmacogenomics Journal.

FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis.

H. Guchelaar, T. Huizinga, J. Swen, 2015, Pharmacogenomics.

Association between -174 interleukin-6 gene polymorphism and biological response to rituximab in several systemic autoimmune diseases.

Javier Martín, G. Robledo, R. Ríos-Fernandez, 2012, DNA and cell biology.

Genetic Polymorphisms in VEGFR Coding Genes (FLT1/KDR) on Ranibizumab Response in High Myopia and Choroidal Neovascularization Patients

X. Díaz-Villamarín, C. Dávila-Fajardo, L. J. Martínez-González, 2022, Pharmaceutics.

Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine

J. C. Barrera, X. Díaz-Villamarín, C. Dávila-Fajardo, 2019, Genes.

Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single‐Patient Data Meta‐Analysis in More Than 15,000 Individuals

Mohamed H. Shahin, P. Deloukas, R. Altman, 2019, Clinical pharmacology and therapeutics.

Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study

Munir Pirmohamed, Emmanuelle Rial-Sebbag, Mats O Karlsson, 2020, Pharmacogenetics and genomics.

IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients

Cristina Lucía Dávila-Fajardo, Javier Martín, G. Robledo, 2013, Molecular Biology Reports.

Pharmacogenomics decision support in the U-PGx project: Results and advice from clinical implementation across seven European countries

M. Pirmohamed, M. Samwald, G. Patrinos, 2022, PloS one.

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

M. Pirmohamed, A. Cambon-Thomsen, Yitian Zhou, 2023, The Lancet.

Genetic Variants Affecting Anti-VEGF Drug Response in Polypoidal Choroidal Vasculopathy Patients: A Systematic Review and Meta-Analysis

X. Díaz-Villamarín, C. Dávila-Fajardo, L. J. Martínez-González, 2020, Genes.

Binding of sulphonated indigo derivatives to RepA-WH1 inhibits DNA-induced protein amyloidogenesis

J. Bravo, M. Maté, R. Giraldo, 2008, Nucleic acids research.

Early events in the binding of the pPS10 replication protein RepA to single iteron and operator DNA sequences.

Rafael Giraldo, M. Lillo, R. Giraldo, 2006, Journal of molecular biology.

A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population

A. Borobia, A. Carcas, H. Tong, 2016, PloS one.

Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate.

H. Guchelaar, J. Swen, C. Dávila-Fajardo, 2013, Pharmacogenomics.

Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients

X. Díaz-Villamarín, C. Dávila-Fajardo, L. J. Martínez-González, 2021, Pharmaceutics.

CORRIGENDUM: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

M. Pirmohamed, A. Cambon-Thomsen, M. Ingelman-Sundberg, 2017, Clinical pharmacology and therapy.

Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE study

G. Patrinos, K. Vasileiou, J. Swen, 2023, Human Genomics.

Association of the FCGR3A-158F/V gene polymorphism with the response to rituximab treatment in Spanish systemic autoimmune disease patients.

Javier Martín, G. Robledo, R. Ríos-Fernandez, 2012, DNA and cell biology.

Influence of the HER2 Ile655Val polymorphism on trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients: a meta-analysis

P. Carmona-Sáez, C. Dávila-Fajardo, L. J. Martínez-González, 2015, Pharmacogenetics and genomics.

Lack of validation of genetic variants associated with anti–tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis

Javier Martín, E. Pérez-Pampín, J. Gómez-Reino, 2014, Arthritis Research & Therapy.

The study protocol for a non-randomized controlled clinical trial using a genotype-guided strategy in a dataset of patients who undergone percutaneous coronary intervention with stent

J. C. Barrera, C. Dávila-Fajardo, L. J. Martínez-González, 2016, Data in brief.

IL2/IL21 region polymorphism influences response to rituximab in systemic lupus erythematosus patients

Javier Martín, G. Robledo, R. Ríos-Fernandez, 2013, Molecular Biology Reports.

Confirmation of −174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome

Javier Martín, A. Balsa, M. M. Moreno Ramos, 2014, Pharmacogenetics and genomics.

Genetic polymorphisms in ADRB1, ADRB2 and CYP2D6 genes and response to beta-blockers in patients with acute coronary syndrome.

C. Dávila-Fajardo, A. Antúnez-Rodríguez, A. Pozo-Agundo, 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Targeted next-generation sequencing panel to investigate antiplatelet adverse reactions in acute coronary syndrome patients undergoing percutaneous coronary intervention with stenting.

J. Triviño-Juárez, C. Dávila-Fajardo, J. Sánchez-Ramos, 2024, Thrombosis research.